How Effective Is Upper Airway Stimulation as an Alternative to CPAP?
Upper airway stimulation (UAS) therapy reduced obstructive sleep apnea severity in patients who had difficulty accepting or adhering to CPAP, this multicenter trial found. The therapy uses an implanted device to stimulate the hypoglossal nerve and prevent airway collapse during sleep. At 12 months, the median apnea-hypopnea index (AHI) fell 68%, from 29.3 to 9.0 events per hour, and the oxygen desaturation index fell 70%, from 25.4 to 7.4 events per hour. This was an uncontrolled, single-group cohort study, not a randomized comparison against CPAP, though a subset of responders went on to a randomized therapy-withdrawal phase that tested whether the benefit depended on the device staying on.
Dr. Kumar’s Take
For patients who cannot tolerate CPAP, this is a meaningful option. Cutting the median AHI from 29.3 to 9.0 events per hour moves a patient out of the moderate-to-severe range, and the oxygen desaturation index moved in parallel, which tells me the airway is actually staying open rather than the scoring shifting around. The mechanism is elegant: instead of splinting the airway with external pressure the way CPAP does, stimulation works from the inside by activating the tongue muscle to maintain airway patency.
The withdrawal phase is the part I find most persuasive. When therapy was turned off, AHI climbed back to 25.8 events per hour, close to where these patients started, while the maintenance group stayed near 7 events per hour. That is about as clean a demonstration of causation as a single-group study can produce. Procedure-related serious adverse events ran under 2%, which is reassuring for an implanted device.
I hold two cautions. This was a selected group, mostly men, mean age 54.5 years, mean BMI 28.4, all of them people who had already failed CPAP. I would not extrapolate these numbers to a heavier or more anatomically varied population without more data. And surgical implantation is a real commitment. For the right candidate who has genuinely exhausted CPAP, I think it is worth the conversation.
Key Findings
The STAR trial enrolled 126 participants with moderate-to-severe obstructive sleep apnea who had difficulty accepting or adhering to CPAP therapy. Of these, 83% were men. The mean age was 54.5 years and the mean body-mass index was 28.4.
At 12 months, the median AHI decreased 68%, from 29.3 to 9.0 events per hour. The oxygen desaturation index, counting the times per hour that blood oxygen drops by at least 4 percentage points, decreased 70%, from 25.4 to 7.4 events per hour. Both results were highly statistically significant.
Secondary measures, including the Epworth Sleepiness Scale and the Functional Outcomes of Sleep Questionnaire, showed reduced effects of sleep apnea and improved quality of life.
The randomized withdrawal phase enrolled consecutive participants who had responded to therapy. Among the 23 assigned to continue therapy, the mean AHI was 8.9 events per hour, essentially unchanged from the 7.2 events per hour recorded in the nonrandomized phase. Among the 23 assigned to withdrawal, AHI rose to 25.8 events per hour compared with 7.6 on therapy, a significant worsening. Oxygen desaturation followed the same pattern.
The rate of procedure-related serious adverse events was less than 2%.
Brief Summary
The STAR trial was a multicenter, prospective, single-group cohort study of upper airway stimulation in patients with obstructive sleep apnea who had difficulty accepting or adhering to CPAP. Participants underwent surgical implantation of an upper airway stimulation device. The primary outcome measures were the apnea-hypopnea index and the oxygen desaturation index at 12 months. The Epworth Sleepiness Scale, the Functional Outcomes of Sleep Questionnaire, and the percentage of sleep time with oxygen saturation below 90% were secondary outcomes.
Study Design
This was a multicenter, prospective, single-group cohort study with no parallel control arm. Participants were surgically implanted with an upper airway stimulation device and followed to 12 months. AHI, defined as the number of apnea or hypopnea events per hour with a score of 15 or above indicating moderate-to-severe apnea, and the oxygen desaturation index served as the primary outcome measures.
Consecutive participants who responded to therapy were then enrolled in a randomized, controlled therapy-withdrawal trial, with 23 participants assigned to continue therapy and 23 assigned to have it withdrawn. That withdrawal phase is what allows the effect to be attributed to the device rather than to the passage of time or to changes in the participants’ habits.
The trial was funded by Inspire Medical Systems.
Results You Can Use
Upper airway stimulation cut the median AHI by 68% in this selected group of CPAP-intolerant patients, bringing the typical participant from 29.3 events per hour down to 9.0. Oxygen desaturation events fell 70%.
The benefit depends on the therapy staying active. When stimulation was withdrawn in the randomized phase, AHI returned to 25.8 events per hour, near the pretreatment range, while participants who continued therapy held at 8.9. This is a treatment that manages the condition, not one that resolves it.
Secondary measures of sleepiness and daily function improved alongside the sleep study numbers, so the objective gains translated into how participants felt and functioned.
Serious adverse events related to the procedure occurred in fewer than 2% of participants.
Why This Matters For Health And Performance
Obstructive sleep apnea carries considerable health risks, and CPAP can mitigate those risks only when patients actually use it. Inadequate adherence is the weak point in the standard treatment. Every patient who abandons CPAP is left carrying the untreated condition.
This trial addresses exactly that gap. For patients who cannot accept or adhere to CPAP, upper airway stimulation produced substantial reductions in both apnea events and oxygen desaturation, along with improvements in sleepiness and daily function. That gives a group with few remaining options a route back to treated sleep apnea.
How to Apply These Findings in Daily Life
- Consider it if CPAP has failed: The trial studied patients who had difficulty accepting or adhering to CPAP, so that is the group these results speak to
- Evaluate candidacy with a specialist: Participants had moderate-to-severe obstructive sleep apnea and a mean BMI of 28.4; a sleep physician can assess whether your case resembles the studied population
- Understand the commitment: This therapy requires surgical implantation of a device
- Expect ongoing therapy, not a cure: Turning the device off returned AHI to near-baseline levels within the withdrawal phase
- Weigh the procedural risk: Procedure-related serious adverse events occurred in fewer than 2% of participants
- Keep up sleep study follow-up: The outcomes here were measured objectively by AHI and oxygen desaturation index, and those are the measures that confirm the device is doing its job
Limitations To Keep In Mind
The authors describe this as an uncontrolled cohort study, with no parallel comparison group receiving another treatment. Participants were a selected population: 83% men, mean age 54.5 years, mean BMI 28.4, all with difficulty accepting or adhering to CPAP. Results may not transfer to patients outside that profile. The therapy requires surgical implantation with associated risks. The trial reported outcomes at 12 months, so this evidence speaks to the first year of therapy. The study was funded by the device manufacturer.
Related Studies And Internal Links
- CPAP vs Oxygen for Sleep Apnea: Cardiovascular Outcomes
- Tirzepatide for Sleep Apnea and Obesity: Breakthrough Results
- CPAP Effects on Blood Pressure in Resistant Hypertension
- Sleep Apnea Screening: STOP-Bang Questionnaire Performance
- How to Sleep Better: Science Daily Playbook
FAQs
How does upper airway stimulation work?
The therapy uses a surgically implanted device to stimulate the upper airway, keeping it from collapsing during sleep. In this trial, that translated into a 68% drop in the median number of apnea and hypopnea events per hour at 12 months.
Who was studied in this trial?
The 126 participants had obstructive sleep apnea and difficulty either accepting or adhering to CPAP therapy. Most were men, at 83%. The mean age was 54.5 years and the mean body-mass index was 28.4.
What happens if the device is turned off?
The trial tested this directly. Among 23 participants randomized to therapy withdrawal, mean AHI rose to 25.8 events per hour, compared with 7.6 while on therapy. Participants who continued therapy stayed at 8.9 events per hour.
How safe was the procedure?
The rate of procedure-related serious adverse events was less than 2%.
Conclusion
Upper airway stimulation reduced the median AHI by 68% and the oxygen desaturation index by 70% at 12 months in patients who could not accept or adhere to CPAP, with sleepiness and daily function improving alongside. The randomized withdrawal phase showed the benefit disappears when the device is switched off, which points to the therapy itself as the cause. This was an uncontrolled cohort study in a selected population, so I read it as strong support for offering stimulation to CPAP-intolerant patients rather than as a head-to-head verdict against CPAP.
